Skip to main content
Full access
Letter to the Editor
Published Online: 1 November 1999

Dr. Reimherr Replies

Publication: American Journal of Psychiatry
To the Editor: The focus of our article was on the optimal length of therapy required to reduce the risk of relapse, which, as Dr. Travers points out, is not the same as the optimal length of therapy, more broadly defined. I strongly agree that determining the optimal length of treatment for depression involves balancing risks and benefits. Indeed, because the issue of safety and tolerability during long-term fluoxe­tine administration is so important, we have addressed these issues in great detail at several scientific meetings (unpublished presentations by Michelsen, 1997, and Beasley, 1998) and in publications (13).
Additionally, Eli Lilly and Company made the complete data set available to each of the five principal investigators (J.Z., J.D.A., F.M.Q., F.W.R., and J.F.R.) for further analysis. The data set could be used for whatever analysis they decided to pursue. This degree of openness is highly unusual in industry-sponsored studies.
This article focused on a comparison of the three points in time in which patients were randomly crossed over from drug treatment to placebo. This narrow comparison helped produce a significant and succinct set of study data. A very pertinent question that might have been posed by Dr. Travers was whether there were unique side effects or risks associated with each of these three crossover points. So far none has been identified.
Finally, to summarize our findings with respect to risk, the data strongly suggest that long-term therapy with fluoxetine is well tolerated and that the risks of early discontinuation of therapy (i.e., the consequences of depressive relapse) far outweigh the risks related to adverse events. All common adverse events specific to fluoxetine treatment during the initiation of therapy declined significantly over time, and previously uncommon categories of adverse events did not become common late in treatment (1).

References

1.
Zajecka J, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Tamura RN, Sundell KL, Michelson D, Beasley CM Jr: Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J Clin Psychiatry 1999; 60:389–394
2.
Zajecka J, Fawcett J, Amsterdam J, Quitkin F, Reimherr F, Rosenbaum J, Michelson D, Beasley C: Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18:193–197
3.
Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rowan M, Beasley CM: Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997: 154:963–969

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1839-b - 1840

History

Published online: 1 November 1999
Published in print: November 1999

Authors

Details

FRED W. REIMHERR, M.D.
Salt Lake City, Utah

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share